Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.

Key facts

Study ID

NCT01414283

Run by

Progenics Pharmaceuticals, Inc.

People needed

52

Starts

2008-10-01

Expected to finish

2013-09-01

Last updated by the study team

2013-11-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of progressive, castration-resistant, metastatic prostate cancer.
• Prior chemotherapy regimens, one of which contains taxane.
• Eastern Cooperative Oncology Group status of 0 or 1

You may not qualify if…

• Clinically significant cardiac disease or severe debilitation pulmonary disease
• Evidence of an active infection requiring ongoing antibiotic therapy
• Any prior treatment with any other therapy targeting PSMA
• History of drug and/or alcohol abuse

Where it is running

• Progenics Pharmaceuticals, Inc. — Tarrytown, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.